Cargando…
Long-term results of ERCP- or PTCS-directed photodynamic therapy for unresectable hilar cholangiocarcinoma
BACKGROUND: Photodynamic therapy (PDT) can be performed as palliative therapy for cholangiocarcinoma, while there is currently insufficient evidence for the efficacy. The aim of this study was to explore the clinical efficacy and safety of endoscopic retrograde cholangiopancreatography (ERCP)- or pe...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437910/ https://www.ncbi.nlm.nih.gov/pubmed/33104917 http://dx.doi.org/10.1007/s00464-020-08095-1 |
_version_ | 1783752255060574208 |
---|---|
author | Li, Zongyan Jiang, Xiaofeng Xiao, Hua Chen, Shaoyi Zhu, Wenfeng Lu, Haiwu Cao, Liangqi Xue, Ping Li, Haiyan Zhang, Dawei |
author_facet | Li, Zongyan Jiang, Xiaofeng Xiao, Hua Chen, Shaoyi Zhu, Wenfeng Lu, Haiwu Cao, Liangqi Xue, Ping Li, Haiyan Zhang, Dawei |
author_sort | Li, Zongyan |
collection | PubMed |
description | BACKGROUND: Photodynamic therapy (PDT) can be performed as palliative therapy for cholangiocarcinoma, while there is currently insufficient evidence for the efficacy. The aim of this study was to explore the clinical efficacy and safety of endoscopic retrograde cholangiopancreatography (ERCP)- or percutaneous transhepatic cholangioscopy (PTCS)-directed PDT combined with stent placement for unresectable hilar cholangiocarcinoma. METHODS: A retrospective analysis was conducted on 62 patients with unresectable hilar cholangiocarcinoma. Thirty patients received PDT using hematoporphyrin combined with biliary stent placement (PDT+stent group), including 22 receiving ERCP-directed PDT and 8 receiving PTCS-directed PDT. Survival time, quality of life, and postoperative adverse events were compared to 32 patients receiving biliary stent placement alone (Stent-only group). RESULTS: After 42 months of follow-up, median survival time was significantly longer in the PDT+stent group than the Stent-only group (14.2 vs. 9.8 months, P = 0.003). In the PDT+stent group, the median survival time was longer in the 6 patients with recurrence after surgical resection than the 24 patients without prior surgical resection (20.0 vs. 13.0 months, P = 0.017). The QOL total scores was significantly higher in the PDT+stent group than the Stent-only group at postoperative 6, 9, and 12 months (P<0.05). There was no significant difference in the incidence of postoperative adverse events between the two groups (24 [38.7%] vs. 20 [29.0%], P = 0.239). CONCLUSION: ERCP- or PTCS-directed PDT + stent placement can prolong the survival of patients with unresectable hilar cholangiocarcinoma, especially those with recurrence and improve quality of life without increasing adverse events. |
format | Online Article Text |
id | pubmed-8437910 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-84379102021-09-29 Long-term results of ERCP- or PTCS-directed photodynamic therapy for unresectable hilar cholangiocarcinoma Li, Zongyan Jiang, Xiaofeng Xiao, Hua Chen, Shaoyi Zhu, Wenfeng Lu, Haiwu Cao, Liangqi Xue, Ping Li, Haiyan Zhang, Dawei Surg Endosc Article BACKGROUND: Photodynamic therapy (PDT) can be performed as palliative therapy for cholangiocarcinoma, while there is currently insufficient evidence for the efficacy. The aim of this study was to explore the clinical efficacy and safety of endoscopic retrograde cholangiopancreatography (ERCP)- or percutaneous transhepatic cholangioscopy (PTCS)-directed PDT combined with stent placement for unresectable hilar cholangiocarcinoma. METHODS: A retrospective analysis was conducted on 62 patients with unresectable hilar cholangiocarcinoma. Thirty patients received PDT using hematoporphyrin combined with biliary stent placement (PDT+stent group), including 22 receiving ERCP-directed PDT and 8 receiving PTCS-directed PDT. Survival time, quality of life, and postoperative adverse events were compared to 32 patients receiving biliary stent placement alone (Stent-only group). RESULTS: After 42 months of follow-up, median survival time was significantly longer in the PDT+stent group than the Stent-only group (14.2 vs. 9.8 months, P = 0.003). In the PDT+stent group, the median survival time was longer in the 6 patients with recurrence after surgical resection than the 24 patients without prior surgical resection (20.0 vs. 13.0 months, P = 0.017). The QOL total scores was significantly higher in the PDT+stent group than the Stent-only group at postoperative 6, 9, and 12 months (P<0.05). There was no significant difference in the incidence of postoperative adverse events between the two groups (24 [38.7%] vs. 20 [29.0%], P = 0.239). CONCLUSION: ERCP- or PTCS-directed PDT + stent placement can prolong the survival of patients with unresectable hilar cholangiocarcinoma, especially those with recurrence and improve quality of life without increasing adverse events. Springer US 2020-10-26 2021 /pmc/articles/PMC8437910/ /pubmed/33104917 http://dx.doi.org/10.1007/s00464-020-08095-1 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Li, Zongyan Jiang, Xiaofeng Xiao, Hua Chen, Shaoyi Zhu, Wenfeng Lu, Haiwu Cao, Liangqi Xue, Ping Li, Haiyan Zhang, Dawei Long-term results of ERCP- or PTCS-directed photodynamic therapy for unresectable hilar cholangiocarcinoma |
title | Long-term results of ERCP- or PTCS-directed photodynamic therapy for unresectable hilar cholangiocarcinoma |
title_full | Long-term results of ERCP- or PTCS-directed photodynamic therapy for unresectable hilar cholangiocarcinoma |
title_fullStr | Long-term results of ERCP- or PTCS-directed photodynamic therapy for unresectable hilar cholangiocarcinoma |
title_full_unstemmed | Long-term results of ERCP- or PTCS-directed photodynamic therapy for unresectable hilar cholangiocarcinoma |
title_short | Long-term results of ERCP- or PTCS-directed photodynamic therapy for unresectable hilar cholangiocarcinoma |
title_sort | long-term results of ercp- or ptcs-directed photodynamic therapy for unresectable hilar cholangiocarcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437910/ https://www.ncbi.nlm.nih.gov/pubmed/33104917 http://dx.doi.org/10.1007/s00464-020-08095-1 |
work_keys_str_mv | AT lizongyan longtermresultsofercporptcsdirectedphotodynamictherapyforunresectablehilarcholangiocarcinoma AT jiangxiaofeng longtermresultsofercporptcsdirectedphotodynamictherapyforunresectablehilarcholangiocarcinoma AT xiaohua longtermresultsofercporptcsdirectedphotodynamictherapyforunresectablehilarcholangiocarcinoma AT chenshaoyi longtermresultsofercporptcsdirectedphotodynamictherapyforunresectablehilarcholangiocarcinoma AT zhuwenfeng longtermresultsofercporptcsdirectedphotodynamictherapyforunresectablehilarcholangiocarcinoma AT luhaiwu longtermresultsofercporptcsdirectedphotodynamictherapyforunresectablehilarcholangiocarcinoma AT caoliangqi longtermresultsofercporptcsdirectedphotodynamictherapyforunresectablehilarcholangiocarcinoma AT xueping longtermresultsofercporptcsdirectedphotodynamictherapyforunresectablehilarcholangiocarcinoma AT lihaiyan longtermresultsofercporptcsdirectedphotodynamictherapyforunresectablehilarcholangiocarcinoma AT zhangdawei longtermresultsofercporptcsdirectedphotodynamictherapyforunresectablehilarcholangiocarcinoma |